House dust mite allergy ultra-short course therapy (Allergy Therapeutics)

N/A

Report date: 2022/03/03 17:33:57

Base Information

Drug NameHouse dust mite allergy ultra-short course therapy (Allergy Therapeutics)
Drug Alias NameAcarovac MPLAcarovac QuattroVaccine agonist of toll-like receptor-4 (TLR-4)
ClassificationVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsRhinitis, Allergic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAllergy Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesAllergy Therapeutics
Inactive CompaniesN/A
Active IndicationsRhinitis, Allergic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A